<?xml version="1.0" encoding="UTF-8"?>
<p>
 <xref rid="pone.0215642.t002" ref-type="table">Table 2</xref> shows the sets of primers used to target genetic sequences that code for the expression of the EBOV GP protein and the ZIKV E protein. EBOV and ZIKV were selected for this validation study because they were responsible for two of the most recent international epidemic emergencies of viral origin. The EBOV variant Makona was the causal agent of the West Africa Ebola epidemics [
 <xref rid="pone.0215642.ref037" ref-type="bibr">37</xref>,
 <xref rid="pone.0215642.ref038" ref-type="bibr">38</xref>], while ZIKV was the causal agent of a recent epidemic event that spanned most of Latin America and a significant portion of the United States in 2016 [
 <xref rid="pone.0215642.ref005" ref-type="bibr">5</xref>â€“
 <xref rid="pone.0215642.ref010" ref-type="bibr">10</xref>].
</p>
